As the U.S. moves toward rescheduling, 2024 research reveals complex truths about cannabis. While daily use raises heart attack risks by 25%, new long-term studies show adult cognition remains resilient, challenging old assumptions. From the “entourage effect” in pain relief to high-potency risks for adolescents, explore the molecular breakthroughs and public health challenges defining the new era of legalization
Executive Order 14370 accelerates cannabis rescheduling to Schedule III, marking a pivotal shift in federal drug policy. This move promises significant economic benefits for the cannabis industry, including tax relief and banking access, while opening doors for critical medical research. However, challenges persist regarding high-potency products, impaired driving, and the continued call for full federal decriminalization amidst evolving public health concerns.
Marijuana edibles are a popular way to consume cannabis. Learn about their effects, dosages, and safety tips.
The 2025 move to Schedule III reclassifies cannabis as a medicinal substance, ending the 280E tax penalty and boosting industry cash flow. While facilitating pharmaceutical research and institutional investment, it maintains federal prohibition for recreational markets.
THC and CBD are primary cannabinoids that interface with the endocannabinoid system to regulate homeostasis. THC provides euphoria and manages nausea or pain, while CBD offers non-intoxicating benefits for epilepsy, anxiety, and inflammation through complex pathways.
Explore the complex world of cannabis in this comprehensive 2026 guide. From botanical debates regarding Sativa and Indica to research on THC, CBD, and the “entourage effect,” we detail the plant’s therapeutic potential and public health risks. Stay updated on global legalization trends, including Germany’s reforms and U.S. rescheduling, to understand the future of this pharmacological revolution.